Shots:
- Knight Therapeutics has amended its agreement with Incyte Biosciences to gain exclusive distribution rights for retifanlimab (Brand name: Zynyz in the US and EU) and axatilimab (Brand name: Niktimvo in the US) in LATAM
- Under the amended deal, Incyte will develop, manufacture, and supply retifanlimab and axatilimab, while Knight will handle regulatory approvals and distribution in LATAM. The partners previously signed a 2021 agreement for Minjuvi and Pemazyre
- Zynyz (retifanlimab) is a PD-1-targeting mAb used with carboplatin and paclitaxel, while Niktimvo (axatilimab) is a first-in-class antibody blocking CSF-1R
Ref: GlobeNewswire | Image: Knight Therapeutics and Incyte | Press Release
Related News:- Incyte’s Monjuvi Regimen Receives the US FDA Approval for R/R Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
